

## FULLY LIVE ONSITE ACTIVITY

# LIVER CANCER:

Updated Review of Clinical Management and Translational Science  
FRIDAY, DECEMBER 16, 2022

### PROGRAM

<b>8:30 – 9:00AM</b>	<b>Registration</b>
<b>9:00 – 9:10</b>	<b>Welcome and Opening</b> <b>Ramon Parsons, MD, PhD</b> , Director, Tisch Cancer Institute, Ward-Coleman Chair in Cancer Research, Director, Mount Sinai Cancer, Mount Sinai Health System Chair, Department of Oncological Sciences
<b>9:10 – 9:40</b>	<b>Achievements of Mount Sinai Liver Cancer Program 2005 - 2022</b> <b>Josep M. Llovet, MD, PhD</b> , Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>9:40 – 10:20</b>	<b>HANS POPPER LECTURE:</b> Introduction: <b>Josep M. Llovet, MD, PhD</b> , Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases  <b>Inflammation, NASH and HCC</b> <b>Mathias Heikenwaelder, MD, PhD</b> Division of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg
<b>10:20 – 10:40AM</b>	<b>Coffee Break</b>
<b>10:40 – 12:00pm</b>	<b>EARLY LIVER CANCER</b> <b>Chairman: Myron E. Schwartz, MD</b> , Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
<b>10:40 – 11:00</b>	<b>Molecular pathology of HCC</b> <b>Swan Thung, MD</b> , Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program
<b>11:00 – 11:20</b>	<b>Imaging for early detection of HCC</b> <b>Bachir Taouli, MD, MS</b> , Department of Radiology, Translational and Molecular Imaging Institute (TMII)
<b>11:20 – 11:40</b>	<b>How surgical approaches might change with neoadjuvant/adjuvant immunotherapy in HCC</b> <b>Myron E. Schwartz, MD</b> , Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute
<b>11:40 – 12:00</b>	<b>SBRT approaches for early HCC</b> <b>Michael Buckstein, MD, PhD</b> , Associate Professor, Department of Radiation Oncology
<b>12:00 – 12:30PM</b>	<b>Lunch Break</b>
<b>12:30 – 2:00PM</b>	<b>INTERMEDIATE &amp; ADVANCED LIVER CANCER</b> <b>Chairman: Josep M. Llovet, MD, PhD</b> , Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>12:30 – 12:50</b>	<b>Role of TARE in the management of HCC</b> <b>Edward Kim, MD</b> , Director of Interventional Oncology, Professor of Radiology and Surgery, Director, Interventional Oncology, Mount Sinai Liver Cancer Program

<b>12:50 – 1:10</b>	<b>New flowchart for molecular and immune therapies for advanced HCC</b> <b>Josep M. Llovet, MD, PhD</b> , Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>1:10 – 1:30</b>	<b>Update on biomarkers of response to systemic therapies</b> <b>Augusto Villanueva, MD, PhD</b> , Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>1:30 – 2:00</b>	<b>First in human trials for neoadjuvant and advanced liver cancer</b> <b>Thomas Marron, MD, PhD</b> , Assistant Director of Immunotherapy and Early Phase Trials, Tisch Cancer Institute, Department of Hematology and Medical Oncology
<b>2:00 – 2:20PM</b>	<b>Coffee Break</b>

### BASIC /TRANSLATIONAL SCIENCE

<b>2:00 – 2:35PM</b>	<b>FLASH COMMUNICATIONS FROM YOUNG INVESTIGATORS</b> Chairman: <b>Scott Friedman, MD</b> , Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program
<b>2:00 – 2:05</b>	<b>Microbiome and HCC</b> <b>Marina Barcena-Varela, PhD</b> , Lujambio Laboratory, Department of Oncological Sciences, Division of Liver Diseases, Tisch Cancer Institute, Mount Sinai Liver Cancer Program
<b>2:05 – 2:10</b>	<b>Translating single-cell to bulk RNA sequencing data to identify responders to checkpoint inhibition in advanced hepatocellular carcinoma</b> <b>Sarah Cappuyns, MD</b> , Visiting Researcher Llovet Laboratory, Division of Liver Diseases, Mount Sinai Liver Cancer Program
<b>2:10 – 2:15</b>	<b>Cell based therapy of NASH/HCC</b> <b>Chittampalli Yashaswini, MD/PhD candidate</b> , Friedman Laboratory, Division of Liver Diseases
<b>2:15 – 2:20</b>	<b>Macrophage diversity in Hepatocellular Carcinoma</b> <b>Pauline Hamon, PhD</b> , Miriam Merad Laboratory, The Tisch Cancer Institute, Marc and Jennifer Lipschultz Precision Immunology Institute at Mount Sinai
<b>2:20 – 2:25</b>	<b>Targeting PRMT5 in hepatocellular carcinoma</b> <b>Elisa Arceci, PhD Candidate</b> , Department of Oncological Sciences, Tisch Cancer Institute
<b>2:25 – 2:35</b>	<b>Primary Results From the Phase 3 LEAP-002 Study: Lenvatinib Plus Pembrolizumab Versus Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma</b> <b>Josep M Llovet, MD, PhD</b> , Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>2:35 – 2:45PM</b>	<b>Discussion</b>

<b>2:45 – 4:05PM</b>	<b>PATHOGENESIS AND NOVEL TARGETS FOR THERAPIES</b> <b>Chairman: Samuel Waxman, MD</b> , Distinguished Service Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences
<b>2:45 – 3:05</b>	<b>Mechanisms of advanced fibrosis and implications for HCC</b> <b>Scott Friedman, MD</b> , Dean of Therapeutic Discovery, Co-Director, Mount Sinai Liver Cancer Program
<b>3:05 – 3:25</b>	<b>Are MYC and Notch actionable targets in HCC?</b> <b>Amaia Lujambio, PhD</b> , Department of Oncological Sciences
<b>3:25 – 3:45</b>	<b>Drug discovery for targeting Wnt signaling in HCC</b> <b>Ernesto Guccione, PhD</b> , Department of Oncological Sciences
<b>3:45 – 4:05</b>	<b>Cholangiocarcinoma: Assessing drug combinations with checkpoint inhibitors</b> <b>Daniela Sia, PhD</b> , Mount Sinai Liver Cancer Program, Division of Liver Diseases
<b>4:05pm</b>	<b>Closing Remarks</b>

**PROGRAM DIRECTOR**  
**JOSEP M. LLOVET, MD, PhD**  
Co-Director Mount Sinai Liver Cancer Program, Professor of Medicine, Division of Liver Diseases

**PROGRAM CHAIRS**  
**SCOTT FRIEDMAN, MD**  
Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

**MYRON E. SCHWARTZ, MD**  
Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute

**SAMUEL WAXMAN, MD**  
Distinguished Service Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences

**GUEST FACULTY**  
**MATHIAS HEIKENWAEELDER, MD, PhD**  
Professor and Department Head, Chronic Inflammation and Cancer, German Cancer Research Center, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Germany

**HOST FACULTY**  
**MICHAEL BUCKSTEIN, MD, PhD**  
Associate Professor, Department of Radiation Oncology

**SCOTT FRIEDMAN, MD**  
Dean of Therapeutic Discovery, Co-Director Mount Sinai Liver Cancer Program, Division of Liver Diseases

**ERNESTO GUCCIONE, PhD**  
Department of Oncological Sciences

**EDWARD KIM, MD**  
Director of Interventional Oncology, Mount Sinai Liver Cancer Program  
Professor of Radiology and Surgery, Icahn School of Medicine at Mount Sinai

**JOSEP M. LLOVET, MD, PhD**  
Co-Director Mount Sinai Liver Cancer Program, Professor of Medicine, Division of Liver Diseases

**AMAIA LUJAMBIO, PhD**  
Department of Oncological Sciences

**THOMAS MARRON, MD, PhD**  
Director, Early Phase Trials Unit, Tisch Cancer Institute, Department of Hematology and Medical Oncology

**RAMON PARSONS, MD, PhD**  
Director, Tisch Cancer Institute, Ward-Coleman Chair in Cancer Research, Director, Mount Sinai Cancer, Mount Sinai Health System, Chair, Department of Oncological Sciences

**MYRON E. SCHWARTZ, MD**  
Clinical Director, Mount Sinai Liver Cancer Program, Director of Liver Surgery, Recanati/Miller Transplantation Institute

**DANIELA SIA, PhD**  
Mount Sinai Liver Cancer Program, Division of Liver Diseases

**BACHIR TAOULI, MD, MS**  
Department of Radiology, Translational and Molecular Imaging Institute (TMII)

**SWAN THUNG, MD**  
Pathology, Molecular & Cell Based Medicine, Mount Sinai Liver Cancer Program

**AUGUSTO VILLANUEVA, MD, PhD**  
Mount Sinai Liver Cancer Program, Division of Liver Diseases

**SAMUEL WAXMAN, MD**  
Distinguished Service Professor of Medicine, Department of Hematology and Medical Oncology, Department of Oncological Sciences

**YOUNG INVESTIGATORS**  
**ELISA ARCECI, PhD Candidate**  
Department of Oncological Sciences, Tisch Cancer Institute

**MARINA BARCENA-VARELA, PhD**  
Lujambio Laboratory, Department of Oncological Sciences, Division of Liver Diseases, Tisch Cancer Institute, Mount Sinai Liver Cancer Program

**SARAH CAPPUYNS, MD**  
Visiting Researcher Llovet Laboratory, Division of Liver Diseases, Mount Sinai Liver Cancer Program

**PAULINE HAMON, PhD**  
Miriam Merad Laboratory, The Tisch Cancer Institute, Marc and Jennifer Lipschultz Precision Immunology Institute at Mount Sinai

**CHITTAMPALLI YASHASWINI, MD/PhD Candidate**  
Friedman Laboratory, Division of Liver Diseases